MEK inhibitors - novel targeted therapies of neurofibromatosis associated benign and malignant lesions

MAP/ERK kinase 1 and 2 (MEK 1/2) inhibitors (MEKi) are investigated in several trials to treat lesions that arise from pathogenic variants of the Neurofibromatosis type 1 and type 2 genes (NF1, NF2). These trials showed that MEKi are capable to shrink volume of low grade gliomas and plexiform neurof...

Descripción completa

Detalles Bibliográficos
Autor principal: Harder, Anja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052700/
https://www.ncbi.nlm.nih.gov/pubmed/33863389
http://dx.doi.org/10.1186/s40364-021-00281-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052700/
https://www.ncbi.nlm.nih.gov/pubmed/33863389
http://dx.doi.org/10.1186/s40364-021-00281-0

Ejemplares similares